Vlastníctvo manažmentu spoločnosti ProMIS Neurosciences
Aká je hodnota metriky Vlastníctvo manažmentu spoločnosti ProMIS Neurosciences?
Hodnota metriky Vlastníctvo manažmentu spoločnosti ProMIS Neurosciences, Inc. je 10.14%
Aká je definícia metriky Vlastníctvo manažmentu?
Vlastníctvo manažmentu (Insider Ownership) je pomer akcií vlastnených akcionármi v rámci firmy (vlastniaci viac než 5% spoločnosti alebo s titulom riaditeľa či vedúceho oddelenia) a všetkých vydaných akcií.
A high value of insider ownership means that those working for the company have a large stake in the success of the company. This is sometimes seen as a sign that those running the company will work hard to ensure its success or believe the company's stock price will rise.
A change in insider ownership may come from exercise of option, stock grant and buying or selling of company shares. A purchase of company share signifies a confidence in the company's future performance by people who know the company best. Therefore, Net Insider buying is also an important indicator for investors.
Vlastníctvo manažmentu spoločností v sektore Health Care sektor na TSX v porovnaní so spoločnosťou ProMIS Neurosciences
Čomu sa venuje spoločnosť ProMIS Neurosciences?
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
Firmy s metrikou vlastníctvo manažmentu podobnou spoločnosti ProMIS Neurosciences
- Hodnota metriky Vlastníctvo manažmentu spoločnosti Galiano Gold je 10.12%
- Hodnota metriky Vlastníctvo manažmentu spoločnosti The North American Income Trust Plc je 10.12%
- Hodnota metriky Vlastníctvo manažmentu spoločnosti Universal Insurance Inc je 10.13%
- Hodnota metriky Vlastníctvo manažmentu spoločnosti Western Alaska Minerals Corp je 10.13%
- Hodnota metriky Vlastníctvo manažmentu spoločnosti Spectrum Pharmaceuticals je 10.14%
- Hodnota metriky Vlastníctvo manažmentu spoločnosti Nearmap Ltd je 10.14%
- Hodnota metriky Vlastníctvo manažmentu spoločnosti ProMIS Neurosciences je 10.14%
- Hodnota metriky Vlastníctvo manažmentu spoločnosti Conquest Resources je 10.15%
- Hodnota metriky Vlastníctvo manažmentu spoločnosti Nephros je 10.15%
- Hodnota metriky Vlastníctvo manažmentu spoločnosti Nephros je 10.15%
- Hodnota metriky Vlastníctvo manažmentu spoločnosti Nephros je 10.15%
- Hodnota metriky Vlastníctvo manažmentu spoločnosti Nephros je 10.15%
- Hodnota metriky Vlastníctvo manažmentu spoločnosti Nephros je 10.15%